피부과 의약품시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 치료법, 유형, 투여 경로, 약물 클래스, 유통 채널, 지역별＆경쟁(2021-2031년)

The Global Dermatological Drugs Market is projected to expand from USD 22.02 billion in 2025 to USD 38.52 billion by 2031, reflecting a compound annual growth rate of 9.77%. This sector comprises pharmaceutical formulations, including topical, oral, and parenteral therapies, developed to diagnose and manage conditions affecting the skin, hair, and nails. The market's growth is largely driven by the rising incidence of chronic skin diseases, such as psoriasis and atopic dermatitis, along with an aging demographic prone to dermatological issues. For instance, the National Eczema Association reported in 2025 that over 10% of the United States population had been diagnosed with some form of eczema, highlighting the critical need for effective therapeutic interventions and the broadening scope of the global market.

Despite this positive outlook, the market faces significant hurdles due to the high costs associated with advanced biologic therapies and novel small molecule drugs. These premium pricing structures often lead to restricted patient access and reimbursement limitations, particularly in developing regions with tighter healthcare budgets. Additionally, rigorous regulatory approval protocols for new chemical entities can prolong market entry and escalate development expenses. Consequently, these financial and regulatory barriers pose serious obstacles that could hinder the widespread adoption of innovative treatments and slow the sector's overall expansion.

Market Driver

The increasing global prevalence of both chronic and acute skin disorders acts as a primary catalyst for market growth, requiring a greater volume of pharmaceutical interventions. With diagnosis rates climbing for conditions ranging from autoimmune diseases to skin malignancies, healthcare systems are compelled to prioritize effective therapeutics. According to the American Cancer Society's "Cancer Facts & Figures 2024," released in January 2024, an estimated 100,640 new cases of invasive melanoma were projected to be diagnosed in the United States within that year. This rising disease burden directly leads to higher prescription volumes for oncology-related dermatological drugs and drives the persistent need for innovative treatment modalities to handle complex patient requirements effectively.

Simultaneously, the competitive landscape is being reshaped by advancements in biologics, small molecules, and targeted therapies, which offer superior efficacy and safety compared to traditional systemic treatments. Pharmaceutical companies are actively broadening their portfolios with novel mechanisms of action, especially for refractory conditions like atopic dermatitis. As reported by Sanofi in February 2024 within their "Full Year 2023 Results," sales of Dupixent, a biologic for atopic dermatitis, reached €10.76 billion due to strong patient demand. Furthermore, the sector is supported by the thriving aesthetic segment; according to AbbVie in 2024, global net revenues for Botox Cosmetic totaled $2.68 billion for the full year 2023, confirming the significant economic contribution of cosmetic dermatology to the total market valuation.

Market Challenge

The substantial cost associated with advanced biologic therapies and novel small molecule drugs constitutes a major challenge hindering the expansion of the Global Dermatological Drugs Market. The premium pricing of these innovative treatments often exceeds the financial capacity of healthcare budgets, forcing payers to implement strict reimbursement restrictions such as step therapy and prior authorization. These cost-containment measures create significant barriers to patient access, effectively preventing a large segment of the eligible population from obtaining prescribed treatments. When coverage is unobtainable, the adoption rate of these high-value drugs slows, which directly limits revenue growth for manufacturers and stalls the sector's financial progress.

This trend of restricted accessibility is confirmed by recent industry data emphasizing the severity of coverage obstacles. In 2024, the National Eczema Association cited a study revealing that 44% of prescriptions for biologic therapies were either delayed or denied by insurers due to stringent coverage protocols. Such elevated denial rates significantly limit the market penetration of advanced formulations. Consequently, the market's inability to efficiently deliver these expensive but effective drugs to patients functions as a critical brake on the overall industry's trajectory.

Market Trends

The integration of artificial intelligence is fundamentally transforming the drug discovery landscape within the dermatological sector. Pharmaceutical companies are increasingly utilizing generative AI models to identify new therapeutic targets and optimize molecule design, thereby significantly reducing the time and capital required to bring new treatments to market. This technological shift is particularly vital for complex skin conditions where traditional screening methods have historically struggled to identify effective candidates. For instance, Almirall announced in a January 2024 press release titled "Almirall Announces Partnership With Microsoft" that it had established a three-year strategic collaboration to deploy generative AI and advanced analytics specifically to accelerate the discovery and development of innovative therapies for medical dermatology.

Concurrently, Janus kinase (JAK) inhibitors are rapidly emerging as a dominant therapeutic class, addressing significant unmet needs in immune-mediated skin diseases such as vitiligo and atopic dermatitis. Unlike broad-spectrum immunosuppressants, these small molecule therapies offer targeted modulation of cytokine pathways, providing high efficacy for patients who may not respond to conventional biologics. The commercial success of these formulations highlights their growing acceptance among prescribers and patients seeking non-steroidal alternatives for chronic conditions. According to Incyte's "2024 Third Quarter Financial Results" from October 2024, net product revenues for Opzelura, a topical JAK inhibitor, reached $139 million for the third quarter, marking a substantial 52% increase compared to the same period in the previous year.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Glaxo Smith Kline PLC
• Sun Pharmaceutical Industries Ltd
• Galderma SA
• Amgen Inc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Almirall, S.A
• Eli Lilly and Company
• Bausch Health Companies Inc.

Report Scope

In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Drugs Market, By Therapy

• Acne
• Psoriasis
• Rosacea
• Alopecia
• Others

Dermatological Drugs Market, By Type

• Prescription
• Over-the-counter

Dermatological Drugs Market, By Route of Administration

• Topical
• Oral
• Parenteral

Dermatological Drugs Market, By Drug Class

• Corticosteroids
• Retinoids
• Antibiotics
• Antifungals
• Calcineurin Inhibitors
• Others

Dermatological Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Dermatological Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Drugs Market.

Available Customizations:

Global Dermatological Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermatological Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Acne, Psoriasis, Rosacea, Alopecia, Others)
  • 5.2.2. By Type (Prescription, Over-the-counter)
  • 5.2.3. By Route of Administration (Topical, Oral, Parenteral)
  • 5.2.4. By Drug Class (Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Dermatological Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Drug Class
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dermatological Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Drug Class
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Dermatological Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Drug Class
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Dermatological Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Drug Class
      • 6.3.3.2.5. By Distribution Channel

7. Europe Dermatological Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Drug Class
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dermatological Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Drug Class
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Dermatological Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Drug Class
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Dermatological Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Drug Class
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Dermatological Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Drug Class
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Dermatological Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Drug Class
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Dermatological Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Drug Class
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dermatological Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Drug Class
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Dermatological Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Drug Class
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Dermatological Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Drug Class
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Dermatological Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Drug Class
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Dermatological Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Drug Class
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Dermatological Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Drug Class
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dermatological Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Drug Class
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Dermatological Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Drug Class
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Dermatological Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Drug Class
      • 9.3.3.2.5. By Distribution Channel

10. South America Dermatological Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Drug Class
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dermatological Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Drug Class
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Dermatological Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Drug Class
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Dermatological Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Drug Class
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dermatological Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Glaxo Smith Kline PLC
• 15.4. Sun Pharmaceutical Industries Ltd
• 15.5. Galderma SA
• 15.6. Amgen Inc
• 15.7. Johnson & Johnson Services, Inc.
• 15.8. Novartis AG
• 15.9. Almirall, S.A
• 15.10. Eli Lilly and Company
• 15.11. Bausch Health Companies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer